planned receipt of any vaccine (authorized or experimental), within 30 days before and after vaccination; prior receipt of an experimental or authorized vaccine with the possibility of impacting the interpretation of the study data (for example, vectorized vaccines by adenovirus, any vaccines against coronavirus); administration of immunoglobulins and / or any blood products in the three months prior to the planned administration of the candidate vaccine; any history of angioedema or anaphylaxis; pregnancy, lactation or willingness / intention to become pregnant during the study; diagnosis or current treatment for cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ); history of severe psychiatric illness that possibly affects your participation in the study; hemorrhagic disorder (eg, factor deficiency, coagulopathy or platelet disorder) or a previous history of significant bleeding or hematoma after im injections or venipuncture; continued use of anticoagulants, such as coumarins and related anticoagulants (for example, warfarin) or new oral anticoagulants (for example, apixaban, rivaroxaban, dabigatran and edoxaban); current suspected or known addiction to alcohol or drugs.

planned receipt of any vaccine (authorized or experimental), within 30 days before and after vaccination; prior receipt of an experimental or authorized vaccine with the possibility of impacting the interpretation of the study data (for example, vectorized vaccines by adenovirus, any vaccines against coronavirus); administration of immunoglobulins and / or any blood products in the three months prior to the planned administration of the candidate vaccine; any history of angioedema or anaphylaxis; pregnancy, lactation or willingness / intention to become pregnant during the study; diagnosis or current treatment for cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ); history of severe psychiatric illness that possibly affects your participation in the study; hemorrhagic disorder (eg, factor deficiency, coagulopathy or platelet disorder) or a previous history of significant bleeding or hematoma after im injections or venipuncture; continued use of anticoagulants, such as coumarins and related anticoagulants (for example, warfarin) or new oral anticoagulants (for example, apixaban, rivaroxaban, dabigatran and edoxaban); current suspected or known addiction to alcohol or drugs.